Fig. 2

PGK1 knockdown inhibits proliferation and enhances cisplatin sensitivity in endometrial cancer cell lines. a. Western blot was performed to confirm knockdown of PGK1 in endometrial cancer cell lines (Ishikawa and HEC1A). α-tubulin was used as a loading control. b. MTT assay was used to evaluate the effects of PGK1 knockdown on cell viability in endometrial cancer cell lines (Ishikawa and HEC1A). c-d. Flow cytometry was used to assess the effect of PGK1 knockdown on apoptosis of endometrial cancer cells (Ishikawa and HEC1A). e-f. Effect of PGK1 knockdown on tumor growth in a Ishikawa cell-induced xenograft endometrial cancer model. g. MTT assay was used to evaluate the effect of PGK1 knockdown on the sensitivity of Ishikawa endometrial cancer cell line to cisplatin and the IC₅₀ value was calculated using GraphPad Prism 6. h. MTT assay was used to test the effect of PGK1 knockdown on the sensitivity of HEC1A endometrial cancer cell line to cisplatin and the IC₅₀ value was calculated using GraphPad Prism 6. i. Western blot was performed to confirm knockdown of PGK1 in cisplatin-resistant endometrial cancer cell line (Ishikawa/DDP). j. MTT assay was used to evaluate the effect of PGK1 knockdown on the sensitivity of Ishikawa/DDP cell line to cisplatin and the IC₅₀ value was calculated using GraphPad Prism 6. Data were shown as mean ± SD based on three independent experiments. *, P < 0.05, **, P < 0.01 compared with shNC group